Open AccessDifferent Effects of Losartan and Moxonidine on Endothelial Function During Sympathetic Activation in Essential Hypertension
Author(s) -
Doumas Michael N.,
Douma Stella N.,
Petidis Kostas M.,
Vogiatzis Kostas V.,
Bassagiannis Ilias C.,
Zamboulis Chris X.
Publication year - 2004
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2004.03707.x
Subject(s) - moxonidine , losartan , medicine , catecholamine , essential hypertension , endocrinology , angiotensin ii , blood pressure , receptor , agonist
The aim of this study was to investigate: 1) the effects of treadmill exercise on plasma catecholamines and endothelin‐1 (ET‐1, a potent vasoconstrictor) levels in hypertensive patients; and 2) the impact of 1‐month therapy with losartan as compared with moxonidine on catecholamine and ET‐1 changes during exercise. Twenty‐eight patients with essential hypertension were randomized in two groups: group A received losartan and group B received moxonidine for 1 month. Plasma catecholamines exhibited an almost 10‐fold increase during exercise (p<0.00001) before treatment. Moxonidine significantly decreased catecholamine levels (p<0.05), while losartan reduction was nonsignificant (p<0.36). Plasma ET‐1 increased significantly during exercise before treatment (p<0.00005). Moxonidine therapy did not affect ET‐1 levels (p<0.88), while losartan resulted in a significant decrease of ET‐1 levels both at baseline and during exercise (p<0.007). These findings suggest a mechanism for the reduced cardiovascular mortality noted with an angiotensin receptor blocker as compared with a sympatholytic agent.